Aldeyra Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BioConnect Virtual Conference
07 January 2022 - 12:00AM
Business Wire
Webcast Available On Demand Beginning at 7:00
a.m. ET Monday, January 10
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a
biotechnology company discovering and developing innovative
therapies for the treatment of immune-mediated diseases, today
announced that Todd C. Brady, M.D., Ph.D., President and Chief
Executive Officer, will participate in a fireside chat at the H.C.
Wainwright BioConnect Virtual Conference.
Dr. Brady’s conversation with Edwin Zhang, Ph.D., MBA, Managing
Director and Senior Healthcare Analyst for H.C. Wainwright, will be
available on demand beginning at 7:00 a.m. ET Monday, January 10,
2022. To view the webcast, log in to the Investors & Media
section of the Aldeyra Therapeutics website at
https://ir.aldeyra.com. The event will remain archived on the
website for 90 days.
About Aldeyra Therapeutics
Aldeyra Therapeutics discovers and develops innovative therapies
designed to treat immune-mediated diseases. Our approach is to
develop therapies designed to modulate immunological systems,
without inhibiting or activating single targets, with the goal of
optimizing multiple pathways at once while minimizing toxicity. Two
of our lead product candidates, reproxalap and ADX-629, target
pre-cytokine, systems-based mediators of inflammation known as RASP
(reactive aldehyde species). Reproxalap is in Phase 3 clinical
trials in patients with dry eye disease and allergic
conjunctivitis. ADX-629, an orally administered RASP modulator, is
in Phase 2 proof-of-concept clinical trials in psoriasis, atopic
asthma, and COVID-19. Our clinical pipeline also includes ADX-2191
(intravitreal methotrexate 0.8%), in Phase 3 clinical testing for
the prevention of proliferative vitreoretinopathy. For more
information, visit https://www.aldeyra.com/ and follow us on
LinkedIn, Facebook, and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220105005960/en/
Corporate: Joshua Reed Aldeyra Therapeutics, Inc.
781-761-4904 ext. 218 jreed@aldeyra.com
Investors & Media: Scott Solomon Sharon Merrill
Associates, Inc. 617-542-5300 ALDX@investorrelations.com
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Apr 2023 to Apr 2024